Cardiopulmonary Stress Testing Systems Market Size and Share
Cardiopulmonary Stress Testing Systems Market Analysis by Mordor Intelligence
The cardiopulmonary exercise testing market is valued at USD 5.80 billion in 2025 and is forecast to reach USD 5.86 billion by 2030, advancing at a 4.5% CAGR. Growth rests in the broader shift from volume-based diagnostics to precision cardiopulmonary evaluation, helped by AI-enabled real-time VO₂ analytics that shorten interpretation time and raise diagnostic consistency. Hospitals, sports laboratories, and rehabilitation centers also view these systems as strategic assets because early physiological insights reduce downstream treatment costs. Portable CPET platforms extend testing into home-based rehabilitation, while wearable sensors feed continuous data to cloud algorithms, linking disease diagnostics with fitness monitoring. North American reimbursement clarity, rising Asia-Pacific chronic-disease burden, and steady European clinical research activity collectively underpin demand for the expanding fleet of AI-ready devices. Meanwhile, mid-tier device makers face a regulatory maze that lengthens launch cycles, keeping bargaining power with hospitals moderate, even as user expectations for seamless workflow integration rise.
Key Report Takeaways
- By product type, cardiopulmonary exercise-testing systems held 25.8% of the cardiopulmonary exercise testing market share in 2024, and the segment is growing fastest at 11.1% CAGR to 2030.
- By end user, hospitals captured 28.3% revenue in 2024, while sports-performance and research labs post the highest projected CAGR of 10.2% through 2030.
- By application, disease diagnostics commanded 25.2% of the cardiopulmonary exercise testing market size in 2024; sports and human-performance assessment is expanding at a 9.3% CAGR to 2030.
- By technology, treadmill-based stress testing generated 27.5% of 2024 revenues, whereas wearable and patch-based CPET systems are projected to rise at 10.3% CAGR.
- By geography, North America led with 29% revenue in 2024; Asia Pacific is advancing at an 8.5% CAGR through 2030.
Global Cardiopulmonary Stress Testing Systems Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Rise in global healthcare expenditure | +1.20% | North America, Europe, selected emerging economies | Medium term (2-4 years) |
Rising prevalence of cardiopulmonary disorders | +1.00% | Asia Pacific, North America | Long term (≥4 years) |
Technological advances in stress-ECG & carts | +0.80% | North America, Europe, expanding Asia Pacific | Short term (≤2 years) |
Favorable reimbursement for diagnostic tests | +0.70% | North America, Europe | Medium term (2-4 years) |
AI-enabled real-time VO₂ analytics adoption | +0.60% | Global, led by North America | Short term (≤2 years) |
Home-based rehab using portable CPET | +0.50% | Developed markets | Medium term (2-4 years) |
Source: Mordor Intelligence
Rise in Global Healthcare Expenditure
Expanding health budgets are shifting hospital decisions away from cost-containment toward value-based procurement of advanced CPET systems that package metabolic carts, stress ECG, and cloud analytics into one console.[1]World Bank, “Hospital Systems Efficiency 2024 Report,” worldbank.org Medicare’s 2024 upgrade to cardiac rehabilitation billing further raises the economic case to deploy such platforms, giving providers long-run revenue certainty. Emerging economies replicate this approach as multi-clinic groups co-finance shared CPET suites to widen access. Lower amortized unit cost plus higher throughput help facilities justify the replacement of legacy ergometers with AI-ready devices.
Rising Prevalence of Cardiopulmonary Disorders
Around 48.6% of US adults lived with cardiovascular disease, while fewer than 24.2% met activity guidelines, pushing hospitals to adopt physiologically rich testing to separate cardiac from pulmonary sources of exercise intolerance.[2]American Heart Association, “2024 Heart Disease and Stroke Statistics Update,” heart.orgIntegrating CPET with invasive hemodynamic monitoring allows earlier detection of exercise pulmonary hypertension, which in turn guides targeted therapy. Aging populations and multimorbidity reinforce the need for comprehensive load-response insight that plain stress ECG misses.
Technological Advances in Stress-ECG & Metabolic Carts
Algorithms now classify limitation patterns at pulmonology-grade accuracy using decision-tree and random-forest models fed by breath-by-breath data. MGC Diagnostics’ Ascent software, FDA-cleared in October 2024, merges pulmonary function and CPET into a single interface that automates report drafting. AI-driven quality-control alerts during testing cut rescans, lifting lab throughput and enhancing patient safety.
Favorable Reimbursement Policies for Diagnostic Testing
Updated Medicare coverage decisions define clear medical-necessity rules for CPET during dyspnea work-ups or pre-operative assessment.[3]Centers for Medicare & Medicaid Services, “Cardiac Rehabilitation Programs: Final Rule 2024,” cms.gov Parallel policy moves in commercial insurance reduce prior-authorization delays. Remote monitoring codes now pay for telerehabilitation sessions tied to validated CPET results, expanding patient pools that can be served without new brick-and-mortar capacity.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Stringent Multi-Region Device Approval Pathways | -0.40% | Global, most restrictive in Europe & North America | Long term (≥ 4 years) |
High Capital & Lifecycle Costs Of Integrated CPET Labs | -0.30% | Global, highest impact in emerging markets | Medium term (2-4 years) |
Shortage Of Trained CPET Technologists | -0.50% | Global, acute in North America & Europe | Medium term (2-4 years) |
Wearable Multiparametric Diagnostics Diverting Demand | -0.20% | North America & Europe, expanding globally | Short term (≤ 2 years) |
Source: Mordor Intelligence
Stringent Multi-Region Device Approval Pathways
The European Medical Device Regulation demands extensive bench data even for incremental upgrades. At the same time, US post-market surveillance can trigger costly recalls, as seen with Vyaire’s Twin Tube incident in April 2024. Divergent cybersecurity requirements further extend timelines for AI-enabled systems, often forcing smaller firms to stage launches region by region.
High Capital & Lifecycle Costs of Integrated CPET Labs
Full CPET suites bundle high-flow analyzers, calibrated treadmills, spirometry stations and network servers, creating an upfront burden that can top USD 0.5 million for a tertiary-care lab. Continuous calibration gases, filter replacements and analyst retraining add recurring overhead, discouraging adoption in facilities that lack a cardiology volume base to amortize costs.
Segment Analysis
By Product Type: CPET Systems Lead Innovation Wave
Cardiopulmonary exercise-testing systems generated 25.8% of 2024 revenue, and this category is pacing the field with 11.1% CAGR. The cardiopulmonary exercise testing market size linked to these systems will expand as integrated gas analyzers and stress ECG modules converge into touchscreen carts that auto-score data. Metabolic carts now self-calibrate in 90 seconds, reducing downtime. Meanwhile, stress blood-pressure monitors and entry-level ECG ergometers retain demand in clinics where budgets cannot yet stretch to full platforms.
Algorithm-based interpretation cements this leadership: random-forest classifiers find mechanical-ventilatory bottlenecks that trainees might overlook, and automated ventilatory-threshold detection supports precise exercise prescriptions. Providers therefore prefer single-vendor bundles that cover cardiopulmonary exercise testing market compliance and remote-monitoring extensions in one purchase.
Note: Segment shares of all individual segments available upon report purchase
By End User: Sports Labs Drive Market Evolution
Hospitals controlled 28.3% expenditure in 2024, yet sports-performance and research labs headline growth at 10.2% CAGR, reflecting rising elite-fitness budgets and university studies. The cardiopulmonary exercise testing market benefits from pro-team demand for daily readiness scoring, and cycle-ergometer protocols fine-tuned to altitude camps. Rehabilitation centers follow suit, folding CPET into post-operative care plans reimbursed under newly expanded cardiac-rehab codes.
Unlike hospital procurement, sports facilities favor portability and rapid setup. Vendors are responding with backpack analyzers weighing under 400 g, Bluetooth-linked to tablets that parse breath-by-breath data through cloud AI, keeping the cardiopulmonary exercise testing market aligned with field-based applications while still compliant with clinical standards.
By Application: Disease Diagnostics Face Performance Assessment Challenge
Disease diagnostics retained 25.2% in 2024 and remains the anchor use case, yet sports and human-performance assessment is rising at 9.3% CAGR. Cardiac surgeons rely on pre-operative CPET when frailty assessment informs risk conversations. In ICUs, weaning protocols now reference exercise capacity recorded before admission.
Conversely, collegiate athletics and corporate wellness programs adopt CPET to benchmark training efficacy, spurring vendors to add gamified dashboards. This interplay widens the cardiopulmonary exercise testing market as single platforms serve both pathological detection and peak-performance mapping, eliminating duplicate capital outlays.

Note: Segment shares of all individual segments available upon report purchase
By Technology: Wearables Challenge Traditional Testing
Treadmill-based stress testing brought in 27.5% of revenue last year, but wearable and patch-based CPET devices show 10.3% CAGR, signaling decentralization. Pressure-sensing insoles, cuffless BP patches, and micro-ultrasound vests feed AI servers that compute equivalent VO₂ kinetics in real time. The cardiopulmonary exercise testing market size for wearables will thus climb quickly as hospitals prescribe home-monitoring kits to post-MI patients who cannot attend in-person sessions.
Tilt-table robotics retains a niche for syncope evaluation, and pharmacologic stress labs serve immobile patients, yet continuous ambulatory data increasingly supplement snapshots collected in those venues. This hybrid landscape cements the cardiopulmonary exercise testing market position as a cross-setting solution rather than a purely lab-based modality.
Geography Analysis
North America generated 29% of 2024 revenue. Adoption is buoyed by CMS rules that reimburse CPET for unexplained dyspnea, plus academic trials that bundle CPET endpoints into cardiovascular drug studies. GE Healthcare’s March 2025 release of Revolution Vibe CT illustrates the region’s appetite for AI-rich cardiology diagnostics that integrate seamlessly with CPET-derived risk scores. Canadian health networks invest in mobile units serving rural communities, broadening access while preserving provincial cost controls.
Asia Pacific is the fastest mover at 8.5% CAGR, propelled by chronic disease growth and hospital build-outs. China’s provincial tenders now stipulate VO₂max capability in county cardiac centers, while Japanese teaching hospitals employ CPET in oncology rehab pathways. India’s tier-two cities add dual-use CPET labs serving both clinical referrals and sports academies, further lifting cardiopulmonary exercise testing market penetration.
Europe maintains robust demand, helped by harmonised clinical guidelines that embed CPET into surgical clearance algorithms. Germany’s DiGA fast-track process incentivises vendors to pair CPET outputs with digital-therapeutic coaching apps, giving patients integrated post-test pathways. The UK National Health Service funds CPET slots in cardiac-rehab settings, citing reductions in unplanned readmissions. Southern Europe relies on EU structural funds to refresh metabolic-cart inventories, ensuring parity with northern centers.

Competitive Landscape
The cardiopulmonary exercise testing market remains moderately fragmented. Top multinationals such as GE Healthcare, Philips and MGC Diagnostics deepen moats by embedding AI that simplifies interpretation workflows. GE’s purchase of the remaining stake in Nihon Medi-Physics in December 2024 broadened its reach in radiopharmaceutical-enabled cardiac imaging, a complement to CPET. Philips invests in ultrasound-based cardiac hemodynamics that can cross-link with VO₂ data streams to create unified cardiovascular dashboards.
Wearable-first entrants are tightening the race. Nanowear secured FDA clearance for its cuffless BP monitor that captures 85 biomarkers, offering a cheaper on-body surrogate to in-lab gas analysis for trend tracking. Start-ups leverage subscription software models, contrasting with capital-sale paradigms of incumbent cart manufacturers. Hospitals weigh these options against cybersecurity risk and integration complexity.
Strategic collaborations proliferate: GE Healthcare aligns with imaging-software houses to deliver non-invasive coronary flow ratios that dovetail with CPET stress protocols, while sports-tech brands partner with university labs for validation studies, thereby entering the clinical reimbursement chain. Patent portfolios around breath-sensor membranes and AI algorithms remain key differentiators that could trigger future consolidation.
Cardiopulmonary Stress Testing Systems Industry Leaders
-
MGC Diagnostics Corporation
-
General Electric Company
-
Koninklijke Philips N V
-
COSMED Srl
-
Nihon Kohden Corp.
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- March 2025: GE Healthcare launched Revolution Vibe CT with AI-powered one-beat cardiac imaging, improving workflow efficiency and reducing energy consumption.
- December 2024: GE Healthcare acquired the remaining 50% of Nihon Medi-Physics, expanding its radiopharmaceutical footprint in Japan’s USD 7 billion molecular-imaging segment.
- October 2024: MGC Diagnostics obtained FDA 510(k) clearance for Ascent software that unifies pulmonary-function and CPET assessment.
- September 2024: GE Healthcare’s Flyrcado (flurpiridaz F 18) injection received FDA approval, enabling the combination of exercise stress testing with cardiac PET imaging.
Global Cardiopulmonary Stress Testing Systems Market Report Scope
The cardiopulmonary stress test is an evaluation of the cardiopulmonary system that allows the physician to assess the functioning of the heart and lungs during exercise. The amount of oxygen consumed by a person while riding a bike or walking on a treadmill is used to assess various conditions like dyspnea, hypertrophic cardiomyopathy, and pulmonary hypertension.
the cardiopulmonary stress testing systems market is segmented by product type (exercise testing systems, stress ECG, stress blood pressure monitors, and other product types), end user (hospitals, specialty clinics, ambulatory surgical centers, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.
By Product Type | Stress Blood-Pressure Monitors | ||
Stress ECG Systems | |||
Exercise Testing Systems | |||
Cardiopulmonary Exercise-Testing (CPET) Systems | |||
Metabolic Carts & Gas-Analysis Modules | |||
By End User | Hospitals | ||
Specialty & Cardiology Clinics | |||
Ambulatory Surgical & Day-Care Centers | |||
Rehabilitation Centers | |||
Sports-Performance & Research Labs | |||
By Application | Disease Diagnostics | ||
Pre-operative Risk Evaluation | |||
Cardiac & Pulmonary Rehabilitation | |||
Sports & Human-Performance Assessment | |||
Critical-Care & ICU Monitoring | |||
By Technology | Treadmill-based Stress Testing | ||
Cycle-Ergometer-based Testing | |||
Robotics-Assisted Tilt-Table (RATT) | |||
Wearable / Patch-based CPET | |||
Pharmacologic Stress Testing Platforms | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia Pacific | China | ||
Japan | |||
India | |||
South Korea | |||
Australia | |||
Rest of Asia Pacific | |||
Middle East & Africa | GCC | ||
South Africa | |||
Rest of Middle East & Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Stress Blood-Pressure Monitors |
Stress ECG Systems |
Exercise Testing Systems |
Cardiopulmonary Exercise-Testing (CPET) Systems |
Metabolic Carts & Gas-Analysis Modules |
Hospitals |
Specialty & Cardiology Clinics |
Ambulatory Surgical & Day-Care Centers |
Rehabilitation Centers |
Sports-Performance & Research Labs |
Disease Diagnostics |
Pre-operative Risk Evaluation |
Cardiac & Pulmonary Rehabilitation |
Sports & Human-Performance Assessment |
Critical-Care & ICU Monitoring |
Treadmill-based Stress Testing |
Cycle-Ergometer-based Testing |
Robotics-Assisted Tilt-Table (RATT) |
Wearable / Patch-based CPET |
Pharmacologic Stress Testing Platforms |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia Pacific | China |
Japan | |
India | |
South Korea | |
Australia | |
Rest of Asia Pacific | |
Middle East & Africa | GCC |
South Africa | |
Rest of Middle East & Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current size of the cardiopulmonary exercise testing market?
The cardiopulmonary exercise testing market is valued at USD 5.80 billion in 2025.
How fast is the cardiopulmonary exercise testing market expected to grow?
The market is projected to expand at a 4.5% CAGR, reaching USD 5.86 billion by 2030.
Which product segment is growing the quickest within the cardiopulmonary exercise testing market?
Cardiopulmonary exercise-testing systems lead growth at an 11.1% CAGR through 2030.
What geographic region shows the highest growth rate for cardiopulmonary exercise testing solutions?
Asia Pacific posts the fastest regional expansion with an 8.5% CAGR between 2025 and 2030.
Page last updated on: June 29, 2025